Menu
Close
Primary links
Newsroom Home
Press Releases
Investor Relations
Corporate
Neurodegenerative diseases
Rare and Genetic diseases
Biosimilars
Collaborations
Events & Webcasts
Sign up for Alerts
All Press Releases
Login
All Press Releases
Filter by
<Any>
Investor Relations
Corporate
Neurodegenerative diseases
Rare and Genetic diseases
-Year
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
Search
Biogen to Present at the Leerink Partners 6th Annual Global Healthcare Conference
2/7/17 4:01 pm EST
Biogen Completes Separation of Global Hemophilia Business, Bioverativ
2/1/17 7:30 am EST
Biogen Reports 2016 Revenues of $11.4 Billion
1/26/17 6:30 am EST
Biogen Fourth Quarter and Year End 2016 Financial Results Webcast Adjusted to 8:00 am on January 26, 2017
1/17/17 4:01 pm EST
Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis
1/17/17 10:42 am EST
Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement
1/17/17 7:30 am EST
New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
1/13/17 7:30 am EST
Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock
1/12/17 8:00 am EST
U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy
12/23/16 4:51 pm EST
Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement
12/22/16 4:36 pm EST
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »
all Press Releases
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Biogen to Present at the Leerink Partners 6th Annual Global Healthcare Conference
2/7/17 4:01 pm EST
Biogen Completes Separation of Global Hemophilia Business, Bioverativ
2/1/17 7:30 am EST
Biogen Reports 2016 Revenues of $11.4 Billion
1/26/17 6:30 am EST
Biogen Fourth Quarter and Year End 2016 Financial Results Webcast Adjusted to 8:00 am on January 26, 2017
1/17/17 4:01 pm EST
Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis
1/17/17 10:42 am EST
Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement
1/17/17 7:30 am EST
New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
1/13/17 7:30 am EST
Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock
1/12/17 8:00 am EST
U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy
12/23/16 4:51 pm EST
Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement
12/22/16 4:36 pm EST
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »